Urine sediment (uSed) in molecular diagnosis of genitourinary cancer: From materials to methods
- 1Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, PR China
Abstract
Urine sediment (uSed) has often been treated as a residual pellet of urinalysis. Here, we reframe it as a biosource for molecular diagnosis in genitourinary (GU) cancer, yet its promise lies less in the molecules it contains than in the methods that make them interpretable. uSed carries tumor-derived DNA, RNA, proteins, and metabolites that capture genetic, epigenetic, transcriptional, proteomic, and metabolic alterations, enabling early detection, risk stratification, therapeutic monitoring, and minimal residual disease surveillance. Its molecular cargo determines biological reach, whereas analytical methods determine the reliability of clinical readouts. This Materials-to-Methods distinction is essential because the field remains rich in discovery but poor in validation: high diagnostic accuracy is frequently reported, yet few uSed assays are prospective, externally validated, or shown to change clinical management. We therefore synthesize uSed as a distinct urine fraction, separate from whole urine, cell-free supernatant, and extracellular vesicles, and evaluate how pre-analytical variability, analytical rigor, and post-analytical evidence grading determine whether molecular signals become clinically actionable. We propose that uSed research must shift from marker discovery to method-defined clinical utility, integrating standardization, external validation, and multi-omic/artificial intelligence approaches within a single translational framework. In this view, uSed is a complementary biosource for molecular diagnosis, not a substitute for tissue biopsy or established clinical pathways.
Related
- Recommendations for the Diagnosis and Treatment of Genitourinary Syndrome of Menopause from the Italian Society of Menopause (SIM) and Italian Society of Gynecology of the Third Age (SIGiTE).
- Current imaging methods and molecular biomarkers for hepatocellular carcinoma diagnosis: a narrative review.
- Scabies Diagnosis: A Narrative Review of Diagnostic Methods, Clinical Misdiagnosis, and Emerging Directions
- Molecular Diagnosis as a Probability of Necessity
- From Measured Accuracy to Patient Outcome: Navigation in Total Hip Arthroplasty and Molecular Diagnosis of Periprosthetic Joint Infection: A Narrative Review
BibTeX
@article{zhao2026urine,
title = {{Urine sediment (uSed) in molecular diagnosis of genitourinary cancer: From materials to methods}},
author = {Jinming Zhao and Xingguo Song},
journal = {The Journal of Liquid Biopsy},
year = {2026},
month = oct,
doi = {10.1016/j.jlb.2026.100680},
url = {https://doi.org/10.1016/j.jlb.2026.100680},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Urine sediment (uSed) in molecular diagnosis of genitourinary cancer: From materials to methods
AU - Jinming Zhao
AU - Xingguo Song
PY - 2026
DA - 2026/10/21
JO - The Journal of Liquid Biopsy
DO - 10.1016/j.jlb.2026.100680
UR - https://doi.org/10.1016/j.jlb.2026.100680
AB - Urine sediment (uSed) has often been treated as a residual pellet of urinalysis. Here, we reframe it as a biosource for molecular diagnosis in genitourinary (GU) cancer, yet its promise lies less in the molecules it contains than in the methods that make them interpretable. uSed carries tumor-derived DNA, RNA, proteins, and metabolites that capture genetic, epigenetic, transcriptional, proteomic, and metabolic alterations, enabling early detection, risk stratification, therapeutic monitoring, and minimal residual disease surveillance. Its molecular cargo determines biological reach, whereas analytical methods determine the reliability of clinical readouts. This Materials-to-Methods distinction is essential because the field remains rich in discovery but poor in validation: high diagnostic accuracy is frequently reported, yet few uSed assays are prospective, externally validated, or shown to change clinical management. We therefore synthesize uSed as a distinct urine fraction, separate from whole urine, cell-free supernatant, and extracellular vesicles, and evaluate how pre-analytical variability, analytical rigor, and post-analytical evidence grading determine whether molecular signals become clinically actionable. We propose that uSed research must shift from marker discovery to method-defined clinical utility, integrating standardization, external validation, and multi-omic/artificial intelligence approaches within a single translational framework. In this view, uSed is a complementary biosource for molecular diagnosis, not a substitute for tissue biopsy or established clinical pathways.
SN - 2950-1954
ER -